Protagonist Therapeutics Inc. (PTGX)
NASDAQ: PTGX · Pharmaceutical Preparations · Newark, CA
Our rating: Neutral
Neutral reaffirmed at $135.90, moderate conviction, November 9, 2026.
Breaks if: The Neutral call turns Cautious if reported free cash flow goes negative in any of the next two quarterly filings, or if the trailing net loss widens beyond $200M without a disclosed ramp in revenue — either condition would mean the cash-generation story is unwinding. It turns Positive if FCF reaches $130M or above within four quarters and the company discloses a revenue line showing year-on-year growth, confirming the commercial or partnership engine is genuinely scaling rather than front-loaded.
Key figures
| Market value | $7.9B |
|---|---|
| Revenue, last 12 months | $552M |
| Net income, last 12 months | $342M |
| Free cash flow, last 12 months | $109M |
| Price to earnings | 23.2× |
| Free cash flow yield | 1.4% |
| Dividend yield | 0.0% |
| Operating margin | 58.6% |
| Return on equity | 39.6% |
| Beta to the S&P 500 | 0.37 |
| Volatility, annualized | 55.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $274M | 5723.6% | $3.07 | −$23M |
| June 30, 2026 | $213M | 3749.2% | $2.29 | $219M |
| March 31, 2026 | $56M | 99.0% | $0.05 | −$49M |
| December 31, 2025 | $7M | −95.6% | $-0.70 | −$37M |
| September 30, 2025 | $5M | 0.8% | $-0.62 | −$2M |
| June 30, 2025 | $6M | 33.1% | $-0.55 | −$30M |
| March 31, 2025 | $28M | −88.9% | $-0.19 | $125M |
| December 31, 2024 | $171M | 184.4% | $2.01 | −$29M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.18B: Claude 72%, Gemini 90%, Mistral 88%
- Diluted earnings per share are above zero: Claude 74%, Gemini 95%, Mistral 92%
- Free cash flow for the quarter is above zero: Claude 42%, Gemini 50%, Mistral 60%
12 ledger entries and 32 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.